Brass Tax Wealth Management Inc. Sells 354 Shares of Johnson & Johnson (NYSE:JNJ)

Brass Tax Wealth Management Inc. decreased its position in Johnson & Johnson (NYSE:JNJ) by 9.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,595 shares of the company’s stock after selling 354 shares during the quarter. Brass Tax Wealth Management Inc.’s holdings in Johnson & Johnson were worth $583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. DGS Capital Management LLC lifted its position in Johnson & Johnson by 17.5% in the 3rd quarter. DGS Capital Management LLC now owns 5,404 shares of the company’s stock worth $876,000 after buying an additional 804 shares during the last quarter. Copley Financial Group Inc. bought a new stake in Johnson & Johnson in the 3rd quarter worth approximately $676,000. Retirement Systems of Alabama lifted its position in Johnson & Johnson by 4.0% in the 3rd quarter. Retirement Systems of Alabama now owns 1,243,090 shares of the company’s stock worth $201,455,000 after buying an additional 48,250 shares during the last quarter. Oddo BHF Asset Management Sas bought a new stake in Johnson & Johnson in the third quarter valued at approximately $406,000. Finally, Inspire Trust Co. N.A. lifted its position in Johnson & Johnson by 12.2% in the third quarter. Inspire Trust Co. N.A. now owns 24,063 shares of the company’s stock valued at $3,900,000 after purchasing an additional 2,610 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.3 %

JNJ stock traded up $0.46 during midday trading on Friday, hitting $146.70. The stock had a trading volume of 1,834,608 shares, compared to its average volume of 7,094,924. The firm has a market cap of $353.20 billion, a price-to-earnings ratio of 21.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The business has a 50-day moving average of $157.01 and a two-hundred day moving average of $156.28. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.66 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.38%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Bank of America reissued a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $174.73.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.